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Abstract 
 
The prognosis for patients diagnosed with disseminated cancer is often poor. Radioimmunotherapy 
(RIT) is a new approach to treat disseminated disease. The aim is to target tumor cells with 
monoclonal antibodies (mAbs) labeled with radionuclides which release cytotoxic particle radiation 
upon decay. The radionuclide 211At, with half-life 7.21h, is an interesting candidate for RIT. It emits an 
α-particle which leaves a short, dense ionization track along its path. The range of the α-particle (<100 
μm) corresponds to a few cell diameters. Thus, with 211At in combination with a tumor-specific mAb, a 
high level of irradiation may be achieved in very small tumors, while, at the same time, the 
surrounding tissue is spared. 
 
In this thesis, the pharmacokinetics of intraperitoneal (IP) 211At-MX35 F(ab’)2 for ovarian cancer was 
investigated in 12 patients partaking in a phase I study. The in vivo distribution was monitored by 
sampling of bodily fluids and gamma camera imaging. Absorbed doses to normal organs and tissues 
were estimated. The peritoneum was subjected to the highest absorbed dose of all investigated tissues 
after the amendment of a thyroid blocking agent. The radiation tolerance of the peritoneum was 
unknown and was therefore studied in an animal model. The absorbed doses associated with 
therapeutic activity levels were found to be well tolerated in a short term perspective. 
 
Exposure to α-particles is however associated with a high risk for cancer induction. The ICRP 
recommends a radiation weighting factor 20 for α-particles. The effective dose provides a tool for 
estimating the risk associated with a procedure involving irradiation. It was estimated to < 2 Sv for a 
general patient undergoing IP 211At-RIT with 300 MBq in 1.5 L icodextrin. 
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